UBS Call 90 SNW 19.12.2025/ DE000UM5E3T2 /
| 2024-06-19 2:43:03 PM | Chg.-0.040 | Bid2:47:18 PM | Ask2:47:18 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 0.910EUR | -4.21% | 0.900 Bid Size: 20,000 |
0.910 Ask Size: 20,000 |
SANOFI SA INHABER ... | 90.00 EUR | 2025-12-19 | Call |
GlobeNewswire
2:00 PM
Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors
GlobeNewswire
06-18
Health Monitor Network ® Appoints Senior VP, Rachel Ferrand, Accelerating Growth
GlobeNewswire
06-18
Belharra Therapeutics Announces Strategic Collaboration with Sanofi to Advance Discovery of Novel Sm...
GlobeNewswire
06-11
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic A...
GlobeNewswire
06-03
Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival ...
GlobeNewswire
05-31
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
GlobeNewswire
05-31
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
GlobeNewswire
05-31
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type ...
GlobeNewswire
05-31
Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with typ...
GlobeNewswire
05-27
Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible ...
GlobeNewswire
05-21
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
GlobeNewswire
05-20
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
GlobeNewswire
05-20
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...
GlobeNewswire
05-20
Shah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax’s 2024 Annual Meet...
GlobeNewswire
05-13
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 20...
GlobeNewswire
05-13
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...
GlobeNewswire
05-13
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
